Logo-jnp
J Nephropathol. 2023;12(2): e21444.
doi: 10.34172/jnp.2023.21444

Scopus ID: 85151333510
  Abstract View: 1424
  PDF Download: 274

Meta-analysis

Association between SGLT2 (sodium-glucose cotransporter-2) inhibitors and bladder cancer in individuals with type 2 diabetes; a systematic review and meta-analysis

Mobin Mohammadtabar 1 ORCID logo, Alireza Fazeli 2 ORCID logo, Najmeh Parsai 3 ORCID logo, Zahra Aboulfathiyarmohammadyar 4 ORCID logo, Erfan Shafiei 5 ORCID logo, Mohamad Khaledi 3 ORCID logo, Elahe Zaremoghadam 6 ORCID logo, Ali Rahnama Sisakht 7 ORCID logo, Saeid Mohammadi 8 ORCID logo, Hossein Mardanparvar 3* ORCID logo

1 Department of Ophthalmology, School of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran
2 Department of Medical Education, Medical Education Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
3 Department of Nursing, Faculty of Nursing and Midwifery, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
4 Student Committee Research, School of Pharmacy (Pharm D), Eastern Mediterranean University of North Cyprus, Famagusta, Cyprus
5 School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
6 Department of Internal Medicine, School of Medicine, Birjand University of Medical Sciences, Birjand, Iran
7 Student Research Committee, School of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
8 Student Research Committee, School of Dentistry, European University of Georgia, Tibilisi, Georgia
*Corresponding Author: Corresponding author: Hossein Mardanparvar, Email: , Email: h.mardanparvar@hums.ac.ir

Abstract

Introduction: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are the most recent pharmaceutical group for type 2 diabetes (T2D) treatment. Evidence indicates contradictory relationships between sodium-glucose cotransporter-2 inhibitors and bladder cancer (BC). Hence, this study aims to investigate the relationship between SGLT2 inhibitors and BC in patients with T2D.

Materials and Methods: This study is a systematic review and meta-analysis based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). International databases including Cochrane, Web of Science, Scopus, PubMed, and Google Scholar were conducted for searching with keywords and without time and language limitations. The reference searching stage continued upgrading until November, 2022. Data analysis was performed with STATA 14 software. The tests with P values lower than 0.05 were considered statistically significant.

Results: The four reviewed studies with a sample size comprising 497 755 individuals indicated the impact of SGLT2 inhibitors on BC of patients with T2D (OR: 0.68; 95% CI: 0.37, 1.2). The effect of dapagliflozin, canagliflozin and empagliflozin administration on the incidence of BC among the T2D patients were (OR: 0.72; 95% CI: 0.39, 1.30), (OR: 0.53; 95% CI: 0.23, 1.20), and (OR: 0.51; 95% CI: 0.20, 1.28), respectively.

Conclusion: The general conclusion of this study revealed that SGLT2 inhibitors did not increase the risk of BC in T2D patients. The analysis of subgroups also indicated that the administration of dapagliflozin, canagliflozin, and empagliflozin also did not increase the risk of BC in T2D patients.

Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO website (ID=CRD42023389014).


Implication for health policy/practice/research/medical education:

This systematic review and meta-analysis was conducted with the aim of investigation of the relationship between SGLT2 (sodium-glucose cotransporter-2) inhibitors and bladder cancer in individuals with type 2 diabetes (T2D). This study showed that these agents did not increase the risk of bladder cancer in T2D patients. The analysis of subgroups also indicated that the administration of dapagliflozin, canagliflozin and empagliflozin did not increase the risk of bladder cancer in type 2 diabetes patients.

Please cite this paper as: Mohammadtabar M, Fazeli A, Parsai N, Aboulfathiyarmohammadyar Z, Shafiei E, Khaledi M, Zaremoghadam E, Rahnama Sisakht A, Mohammadi S, Mardanparvar H. Association between SGLT2 (sodium-glucose cotransporter-2) inhibitors and bladder cancer in individuals with type 2 diabetes; a systematic review and meta-analysis. J Nephropathol. 2023;12(2):e21444. DOI: 10.34172/jnp.2023.21444.

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 1425

Your browser does not support the canvas element.


PDF Download: 274

Your browser does not support the canvas element.

Submitted: 17 Nov 2022
Accepted: 26 Jan 2023
ePublished: 05 Feb 2023
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)